<DOC>
	<DOCNO>NCT00967447</DOCNO>
	<brief_summary>Open , prospective , uncontrolled , observational cohort study .</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy Pradaxar Prevention Venous Thromboembolism Mexican Population Undergoing Elective Total Hip Knee Replacement Surgery</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<criteria>Inclusion criterion : patient age 18 year undergo elective total hip knee replacement surgery Written inform consent obtain data collection source data verification . Exclusion criterion : According approve label follow patient treat PradaxarÂ® 220mg q.d . : age &gt; 75 year renal impairment ( creatinine clearance &lt; 50ml/min ) patient concomitant therapy amiodarone verapamil . elevate liver enzymes &gt; 2 upper limit normal ( ULN ) / hepatic impairment liver disease expect impact survival anaesthesia postoperative indwell epidural catheter hypersensitivity dabigatran etexilate excipients active clinically significant bleed organic lesion risk bleed spontaneous pharmacological impairment haemostasis except aboveincluded patient group concomitant treatment quinidine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>